A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
• •Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
• •Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
• •Clinically significant cardiac disease or risk factors at screening
• •Insufficient bone marrow function at screening:
• •Infections:
• •Known history of testing positive for Human Immunodeficiency Virus infection.
• •Active Hepatitis B and / or Hepatitis C.
• •Active, documented COVID-19 infection
• •Known history of tuberculosis
• •Any serious uncontrolled infection (acute or chronic).
• •Systemic chronic steroid therapy (\>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.